VNDA - Vanda Pharmaceuticals Inc.

VNDA Stock Chart

VNDA Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical firm headquartered in Washington, D.C., specializes in developing and commercializing therapies aimed at addressing significant unmet medical needs. The company's current portfolio includes HETLIOZ, approved for non-24-hour sleep-wake disorders, and Fanapt oral tablets, indicated for schizophrenia treatment.

In addition to its marketed products, Vanda Pharmaceuticals is actively advancing several promising candidates through its robust pipeline. Notably, HETLIOZ (tasimelteon) is under investigation for applications including jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum disorders, and delayed sleep phase disorder. Similarly, Fanapt (iloperidone) is being explored for bipolar disorder and through a long-acting injectable formulation program for schizophrenia.

The company's pipeline extends to Tradipitant (VLY-686), a neurokinin-1 receptor (NK-1R) antagonist targeted at treating conditions such as atopic dermatitis, gastroparesis, and motion sickness. Other compounds in development include VTR-297, a histone deacetylase inhibitor with potential applications in hematologic malignancies and oncology, and VQW-765, a nicotinic acetylcholine receptor partial agonist intended for psychiatric disorders.

Operating across the United States, Europe, and Israel, Vanda Pharmaceuticals continues to expand its reach in the global pharmaceutical market. Founded in 2002, the company remains dedicated to advancing innovative therapies that improve patient outcomes in areas of critical medical need.

VNDA Revenue Chart

VNDA Earnings

Analyst Ratings